now would be a good time for share buyback, page-27

Greyhound, not sure why BTA should get rid of pipeline developments.... I'm sure they will continue to pursue their early licensing model when appropriate...

I assume they threw an extra $25M at getting BTA798 to Phase III because of the pandemic cash, as well as lack of interest (which I find strange as the guys pushing the previous HRV candidate, Plencoril, had no problems licensing out there's back in the day, as well as a number of other big Pharmas having a stab at HRV).

Still, LANI alone is exciting.... Roche generated $10 billion turnover over 10 years on Tamiflu... if we can replicate half of that or more we'll be sitting pretty...